Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology reported a key clinical milestone for its lead cancer therapy ateganosine, a telomere-targeting drug being tested in advanced non-small cell lung cancer (NSCLC). The company activated the first U.S. site in its ongoing international Phase 2 THIO-101 expansion trial, with the initial location at Summit Medical Group in New Jersey and plans for four additional U.S. sites in 2026.
The third-line NSCLC evaluation in the U.S. is supported by a $2.3 million grant from the National Institutes of Health. The trial, which already has 44 active sites across six countries in Europe and Asia, is studying ateganosine both as monotherapy and in sequence with cemiplimab (Libtayo). MAIA highlights prior THIO-101 results showing disease control, response rates, and overall survival above standard-of-care benchmarks, including eight patients with overall survival beyond two years, while noting the regimen has shown an acceptable safety profile to date. Ateganosine holds FDA Fast Track designation for advanced NSCLC.
MAIA Biotechnology CEO Vitoc Vlad received a grant of 800,000 stock options as equity compensation. The options give him the right to buy 800,000 shares of common stock at an exercise price of $1.28 per share and expire on April 10, 2036.
The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, Vlad holds 800,000 options directly, and the filing shows no open-market stock purchases or sales.
MAIA Biotechnology’s Chief Scientific Officer Sergei Gryaznov received a grant of 400,000 stock options to acquire common shares at an exercise price of $1.28 per share. These options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan as part of equity-based compensation.
The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining options vesting in equal monthly installments over the following 36 months. After this grant, Gryaznov holds 400,000 stock options directly, according to the filing.
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.
MAIA Biotechnology reports that net proceeds from its $33 million March 2026 public common stock offering are expected to fully fund its ongoing pivotal Phase 3 THIO-104 trial of ateganosine in third-line non-small cell lung cancer (NSCLC).
The FDA has granted ateganosine Fast Track designation in this setting. THIO-104 is a global, multicenter, open-label Phase 3 study comparing ateganosine sequenced with a checkpoint inhibitor against chemotherapy in a 1:1 randomization of up to 300 patients, using median overall survival and safety as primary objectives. Interim Phase 3 data are expected next year and may support discussions with the FDA about potential early full commercial approval in third-line NSCLC if results are consistent with prior Phase 2 data.
MAIA Biotechnology, Inc. will hold its 2026 annual stockholders meeting virtually on May 21, 2026 at 10:00 a.m. CT via www.virtualshareholdermeeting.com/MAIA2026. Only holders of the 60,671,491 shares of common stock outstanding as of March 23, 2026 may vote, with one vote per share and a quorum requirement of 30,335,747 votes.
Stockholders will elect two Class I directors and vote on ratifying Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee membership, executive compensation, related-party private placements involving directors and a 5% stockholder, and the company’s equity incentive plans and governance policies.
MAIA Biotechnology, Inc. director Steven M. Chaouki received a grant of stock options for 27,907 shares of common stock on March 31, 2026. The options carry an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options as equity compensation. He was awarded 27,258 stock options on March 31, 2026 with an exercise price of $1.40 per share, each option representing one share of common stock.
The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan, vest 100% on the grant date, and are exercisable beginning March 31, 2026. Following this grant, Guerrero holds 27,258 stock options directly, with the options scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Louie Ngar Yee received a grant of stock options for 33,748 shares of common stock. The options were granted on March 31, 2026 at an exercise price of $1.40 per share, vest 100% on the grant date, and are immediately exercisable.
Following this grant, he holds 33,748 stock options directly, which are scheduled to expire on March 31, 2036.